An interview with prof. dr. Martin Boeree A considerably higher dose of the anti-tuberculosis drug rifampicin has been found to be safe according to a recent publication by PanACEA. Higher dosing of rifampicin may lead to a shorter / more efficacious treatment for tuberculosis with less resistance development. With this finding PanACEA researchers complete a…
Read more Shorter treatment may be possible with higher rifampicin doses
The St Andrews group’s most recent paper has been published as a perspective piece in the International Journal of Tuberculosis and Lung Disease.The collaboration between the Schools of Medicine, Applied Mathematics and Computer Science provides an overview of the different types of model that can be applied to tuberculosis clinical trials. Importantly, it provides a…
In the afternoon of 20th of February a ninety minutes interactive workshop on community engagement was held. The inspiring Erica Sanga, Community Engagement Coordinator at NIMR Mwanza, Tanzania, led the workshop. During this workshop, participants from different sites shared their experiences and challenges on community engagement activities. Participants discussed their best practices for successful engagement…
Delegates from all of our collaborators in SimpliciTB TB travelled from across the world to attend the annual face to face General Assembly (GA) meeting in Mbeya, Tanzania. Trial progress was reported, with a focus on recruitment and medical monitoring. An important development was the launch of the Capacity Development programme that allows members of…
For the 10th annual face to face meeting the PanACEA consortium came together in Mbeya, Tanzania, on 19-20 February 2020. This year our partner Mbeya Medical Research Centre (NIMR MMRC) hosted the event. The warm hospitality and great organisation of the team made for a very positive meeting environment. We were off to a great…
Monday 9th of December the PanACEA General Assembly (GA) met again for its quarterly assembly to report and discuss the progress of the project. The first phase of the BTZ043 trial has started at the end of November at UCTLI and TASK Applied Science. Preparations for the SUDOCU and PHENORIF trials are progressing. Next time,…
The new drug substance BTZ043 is being tested on patients for the first time in a Phase II study performed by the PanACEA consortium. The trial is carried out in Cape Town, South Africa at TASK Applied Science Clinical Research Centre and the University of Cape Town Lung Institute (UCTLI). The study is funded by…
We are pleased to announce that our consortium has added two trials to its portfolio. The SUDOCU and PHENORIF trials replace the Q203 study that was initially planned in the Grant Agreement. The trials will take place in South Africa and Tanzania in 2020. Having established the maximum tolerated dose of rifampicin in the HIGHRIF…
Read more PanACEA adds SUDOCU and PHENORIF trials to portfolio
The PanACEA HIGHRIF trial that started in the first phase of PanACEA has continued in the current programme and has succesfully come to an end. The maximum tolerated dose of rifampicin was identified at 40mg/kg. Martin Boeree recently presented the results at The 50th Union World Conference on Lung Health in Hyderabad, India. The publication…
Ifakara Health Institute
Bagamoyo, Tanzania
